Microbiome Therapeutics Poised to Redefine Drug Discovery and Precision Medicine, Says Leucine Rich Bio Co-Founder
核心洞察
Microbiome therapeutics are emerging as a transformative force in drug discovery by explaining differential treatment responses among patients with the same diagnosis.
Dr. Debojyoti Dhar of Leucine Rich Bio (搜索) emphasizes that microbiome communities impact drug metabolism, immune response, and disease development, particularly in oncology (搜索), autoimmunity (搜索), and metabolic diseases (搜索).
India must generate its own microbiome reference data rather than relying on Western datasets, as diet, environment, and genetics differ significantly across populations.
Microbiome therapeutics are emerging as the future engine of drug discovery and personalized healthcare, fundamentally transforming how diseases are understood, prevented, and treated, according to Dr. Debojyoti Dhar, co-founder and director of Leucine Rich Bio (搜索).
In an interview with Pharmabiz, Dr. Dhar outlined a vision in which the human microbiome — the vast community of microorganisms residing in and on the body — becomes a central pillar of next-generation precision medicine. She cautioned that microbiome-based treatments are frequently misunderstood as merely another type of probiotic, when in fact their true potential lies in recognizing the microbiome as a measurable biological system capable of explaining why different people with the same diagnosis respond differently to a given treatment.
A Paradigm Shift in Drug Discovery
For decades, drug discovery efforts have focused on identifying molecular targets within the human body. Dr. Dhar argued that this approach represents only partial knowledge of human biology. "In the next wave of innovation, one should take into account microbiome communities impacting drug metabolism, immune response and disease development," she said, warning that designing treatments without this consideration yields therapies built on incomplete biological understanding.
This paradigm shift carries particular significance for oncology (搜索), autoimmunity (搜索), and metabolic diseases (搜索), where recent studies indicate that the composition of microbiota has direct implications for therapeutic outcomes. Dr. Dhar predicted that medicine will move from simply asking whether a drug works to identifying the specific microbiome profiles in which it works best — a transition that would redefine both clinical trial design and the practice of precision medicine.
Advancing, Not Replacing, Mainstream Medicine
Microbiome therapeutics will not replace mainstream medicine but will advance it, Dr. Dhar emphasized. The future, she explained, lies in using microbial biomarkers to develop precise therapies tailored to individual biological profiles rather than relying on population averages. "Developing the intelligence of microbiome today is not only about improving diagnostics, but creating the biological basis of next generation precision medicines," she stated.
The Case for India-Specific Microbiome Data
A critical challenge identified by Dr. Dhar is the reliance on foreign microbiome reference data to interpret Indian biology. India's diet, environmental exposures, antibiotic use patterns, and genetic makeup all differ substantially from Western populations, yet much of the globally available microbiome information may not adequately capture Indian biology.
"By continuing to interpret our biology using foreign microbiome data, there is a possibility to miss key clinical applications that are specific only to Indians," Dr. Dhar warned. She called for generating Indian-specific data rather than merely conducting research that validates discoveries made elsewhere. Countries like India, she noted, have the potential to carry out original science rather than simply validating international findings.
From Research to Clinical Practice
Dr. Dhar stressed that findings from microbiome research should not remain confined to academic publications. Instead, they must be converted into standardized, clinically actionable data that can be readily interpreted by physicians, nutritionists, and other healthcare professionals. Achieving this will require collaborations among biotech companies, hospitals, academia, and regulators to facilitate data sharing, validate research outcomes, and accelerate the integration of microbiome-based innovations into clinical practice.
India, with its unparalleled population diversity and rapidly advancing digital healthcare ecosystem, is positioned to become a global leader in microbiome research and innovation. "By integrating these strengths with robust microbiome science, our country has the potential to move beyond merely adopting international scientific advancements, instead we can contribute to original, globally relevant discoveries," Dr. Dhar concluded.